2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

lysosomal enzyme

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

2

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16594
    Lactacystin
    5+ Cited Publications

    		 Proteasome Cathepsin Apoptosis Cardiovascular Disease Infection Neurological Disease Cancer
    Lactacystin is a potent, orally active, irreversible, cell-permeable, selective 20S proteasome inhibitor (IC50 = 4.8 μM). Lactacystin also inhibits the lysosomal enzyme cathepsin A. Lactacystin inhibits cell growth and induces apoptosisand cell cycle arrest, and has antiviral and antioxidative activity. Lactacystin induces neurite outgrowth and hypertension. Lactacystin has the potential for the research of cancer, Neurological Disease, hypertension and Malaria, and so on [2] [6] .
    Lactacystin
  • HY-P2803
    Beta-glucuronidase (Escherichia coli)
    1 Publications Verification

    		 β-glucuronidase Metabolic Disease
    Beta-glucuronidase is a glycosyl hydrolase that hydrolyzes β-glucuronic acid and sulfate esters in urine and other biological fluids, and then releases β-glucuronate .
    Beta-glucuronidase (Escherichia coli)
  • HY-128144
    Lalistat 2
    3 Publications Verification

    		 Lipase Metabolic Disease
    Lalistat 2 is an inhibitor of many lipases especially Lysosomal acid lipase (LAL, IC50 = 152 nM), which is a key enzyme that degrades neutral lipids at an acidic pH in lysosomes. Lalistat 2 is commonly used to investigate the cell-specific functions of LAL and LAL deficiency in vitro, as well as specifically measure LAL activity in human blood samples or cells .
    Lalistat 2
  • HY-147976
    Glucocerebrosidase-IN-1

    		Glycosidase Neurological Disease Metabolic Disease
    Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .
    Glucocerebrosidase-IN-1
  • HY-P1759
    N-CBZ-Phe-Arg-AMC

    Z-FR-AMC

    		 Cathepsin Others
    N-CBZ-Phe-Arg-AMC (Z-FR-AMC) is a cathepsin substrate used in assessment activity of lysosomal cathepsin enzymes .
    N-CBZ-Phe-Arg-AMC
  • HY-131703
    UGT8-IN-1
    1 Publications Verification

    		 UGT Metabolic Disease
    UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders .
    UGT8-IN-1
  • HY-126306
    Deoxyfuconojirimycin hydrochloride

    		Glycosidase Others
    Deoxyfuconojirimycin hydrochloride is a highly specific α-L-fucosidase inhibitor, with a Ki value of 10 nM against human liver lysosomal α-L-fucosidase and a Ki value of 140 nM against Charonia lampas α-L-fucosidase. Deoxyfuconojirimycin hydrochloride completely inhibits the activity of all soluble α-L-fucosidases in human liver, including multiple post-translationally generated enzyme forms. Deoxyfuconojirimycin hydrochloride exhibits no anti-human immunodeficiency virus activity .
    Deoxyfuconojirimycin hydrochloride
  • HY-P1759B
    N-CBZ-Phe-Arg-AMC TFA

    Z-FR-AMC TFA

    		 Cathepsin Others
    N-CBZ-Phe-Arg-AMC (Z-FR-AMC) TFA is a cathepsin substrate used in assessment activity of lysosomal cathepsin enzymes .
    N-CBZ-Phe-Arg-AMC TFA
  • HY-132177
    α-L-Fucosidase, Microorganism
    1 Publications Verification

    EC 3.2.1.51; FUC

    		 Endogenous Metabolite Cancer
    α-L-Fucosidase, Microorganism (EC 3.2.1.51) is an enzyme that catalyzes the chemical reaction. Serum activity of α-L-Fucosidase, Microorganism, a lysosomal enzyme present in all mammalian cells, has been proposed as a marker of hepatocellular carcinoma (HCC) .
    α-L-Fucosidase, Microorganism
  • HY-P1759A
    N-CBZ-Phe-Arg-AMC hydrochloride

    Z-FR-AMC hydrochloride

    		 Cathepsin Others
    N-CBZ-Phe-Arg-AMC (Z-FR-AMC) hydrochloride is a cathepsin substrate used in assessment activity of lysosomal cathepsin enzymes .
    N-CBZ-Phe-Arg-AMC hydrochloride
  • HY-42709
    Z-Val-Ala-OH

    Carbobenzoxy-L-valyl-L-alanine

    		 Amino Acid Derivatives Cancer
    Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .
    Z-Val-Ala-OH
  • HY-W654272
    4-Methylumbelliferyl-α-L-iduronide 2-sulfate sodium

    4-MU-α-idoa 2-sulfate sodium

    		 Fluorescent Dye Metabolic Disease
    4-Methylumbelliferyl-α-L-iduronide 2-sulfate (4-MU-α-idoa 2-sulfate) sodium is a fluorogenic substrate of iduronate-2-sulfatase (I2S). 4-Methylumbelliferyl-α-L-iduronide 2-sulfate sodium can be hydrolyzed by lysosomal enzyme α-l-iduronidase (IDUA) and release the fluorophore 4-Methylumbelliferone (HY-N0187). 4-Methylumbelliferyl-α-L-iduronide 2-sulfate sodium can be used to detect Hurler syndrome .
    4-Methylumbelliferyl-α-L-iduronide 2-sulfate sodium
  • HY-147976A
    Glucocerebrosidase-IN-1 hydrochloride

    		Glycosidase Neurological Disease
    Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 hydrochloride can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .
    Glucocerebrosidase-IN-1 hydrochloride
  • HY-P99694
    Lepunafusp alfa

    JR-171

    		 Transferrin Receptor Neurological Disease
    Lepunafusp alfa (JR-171) is a BBB-penetrable fusion protein consisting of J-Brain Cargo and IDUA (a lysosomal enzyme, α-L-iduronidase). Lepunafusp alfa can reduce concentration of heparan sulfate (HS) and dermatan sulfate (DS). Lepunafusp alfa can be used for research of mucopolysaccharidosis type I .
    Lepunafusp alfa
  • HY-P5377
    Abz-HPGGPQ-EDDnp

    Cathepsin K substrate

    		 Ser/Thr Protease Others
    Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)
    Abz-HPGGPQ-EDDnp
  • HY-P2858
    β-Mannosidase

    		Glycosidase Metabolic Disease
    β-Mannosidase is a lysosomal exo‑acting enzyme. β-Mannosidase catalyzes hydrolysis of β‑1,4‑linked mannosides, non‑reducing terminal mannoses in N‑glycoproteins, and Man‑β‑1,4‑GlcNAc linkages to release mannose. β-Mannosidase contributes to glycoprotein catabolism and supports Bifidobacteria colonization via N‑glycan depolymerization. β-Mannosidase can be used for the research of β-mannosidosis and β-mannosidase deficiency .
    β-Mannosidase
  • HY-113484
    Leukotriene B5

    LTB5

    		 Leukotriene Receptor Cancer
    Leukotriene B5 (LTB5) is a leukotriene with diverse biological activities. It is a metabolite of eicosapentaenoic acid formed through the 5-lipoxygenase (5-LO) pathway. LTB5 increases contraction of bullfrog lung strips ex vivo in a concentration-dependent manner. In vivo, LTB5 (100 nM) reduces tumor volume in mice injected with Tm1 murine melanoma cells. LTB5 also elicits chemokinesis and lysosomal enzyme release from polymorphonuclear leukocytes (PMNLs) 20- to 30-fold less, and induces platelet aggregation 8-fold less, potently than LTB4.
    Leukotriene B5
  • HY-178202
    5-C-phenethyl-DNJ

    		Glycosidase Metabolic Disease
    5-C-phenethyl-DNJ is a selective α-glucosidase GAA inhibitor, with its Ki value for rhGAA being 0.81 μM. 5-C-phenethyl-DNJ exhibits extremely high selectivity for GANAB, GBA1, and GBA2. 5-C-phenethyl-DNJ can be used for the study of Pompe disease .
    5-C-phenethyl-DNJ
  • HY-N3855
    Erythrabyssin II

    		Autophagy Apoptosis Cancer
    Erythrabyssin II (EL-19) is a potent late-stage autophagy inhibitor that blocks the fusion of autophagosome and lysosome. Erythrabyssin II leads to the accumulation of autophagic substrates and does not impair lysosomal pH or lysosomal enzyme activity. Erythrabyssin II suppresses ovarian cancer organoid activity and induces apoptosis. Erythrabyssin II can be used for the study of ovarian cancer .
    Erythrabyssin II
  • HY-P4404
    Abz-GIVRAK(Dnp)

    		Cathepsin Others
    Abz-GIVRAK(Dnp) is the most efficient substrate for cathepsin B and is highly selective for this enzyme among lysosomal cysteine proteases. After Abz-GIVRAK(Dnp) is hydrolyzed, aminoacylbenziminosulfosuccinic acid (Abz-SAS) is released, and dinitrobenzoyl (Dnp) is also released. The product of this hydrolysis reaction, Abz-SAS, is fluorescent under ultraviolet light and can emit a fluorescent signal .
    Abz-GIVRAK(Dnp)
  • HY-P10669
    NDI-Lyso

    		Caspase Apoptosis Cancer
    NDI-Lyso is a lysosome-targeted anticancer agent that induces the formation of rigid long fibers in cancer cell lysosomes through an enzyme-instructed self-assembly (EISA) mechanism catalyzed by cathepsin B. This process triggers lysosomal swelling, membrane permeabilization (LMP), and membrane disruption, ultimately leading to cancer cell apoptosis via a non-classical caspase-independent pathway. NDI-Lyso exhibits significant selective anticancer activity in various cancer cell lines and drug-resistant cancer cells (IC50 ~10 μM) while showing low toxicity to normal cells (IC50 > 60 μM) .
    NDI-Lyso
  • HY-167924
    Ono 3307 free base

    		Kallikrein Thrombin Ser/Thr Protease Inflammation/Immunology
    Ono 3307 Free base is a novel synthetic protease inhibitor that exhibits protective effects against acute pancreatitis by preventing hyperamylasemia and pancreatic edema. Ono 3307 Free base also inhibits the redistribution of lysosomal enzymes in acinar cells and mitigates lactic dehydrogenase discharge. Ono 3307 Free base effectively reduces cathepsin B leakage from lysosomes in a dose-dependent manner. Ono 3307 Free base is able to target trypsin (Ki=48 nM), thrombin (Ki=0.18 μM), plasma kallikrein (Ki=0.29 μM), plasmin (Ki=0.31 μM), pancreatic kallikrein (Ki=3.6 μM), and chymotrypsin (Ki=47 μM).
    Ono 3307 free base
  • HY-132177J
    α1-3,4 Fucosidase, Sweet almond

    		Endogenous Metabolite Metabolic Disease
    α1-3,4 Fucosidase, Sweet almond is an enzyme that breaks down fucose. Fucosidosis is an autosomal recessive lysosomal storage disease caused by defective alpha-L-fucosidase with accumulation of fucose in the tissues.
    α1-3,4 Fucosidase, Sweet almond
  • HY-185306
    Morfamquat dichloride

    PP 745

    		 Herbicide Phosphatase β-glucuronidase Metabolic Disease
    Morfamquat dichloride (PP 745) is a bipyridine herbicide. Acute poisoning by Morfamquat dichloride strongly stimulates the reticuloendothelial system, causes lysosomal membrane damage and enzyme leakage, and interferes with the function of hepatocyte Golgi apparatus and related glucose metabolic pathways. Morfamquat dichloride significantly increases the activities of acid phosphatase and β-glucuronidase, exerting toxic effects on mice, while pre-administration of vitamin E alleviates such toxicity .
    Morfamquat dichloride
  • HY-182616
    CH-123

    		β-glucuronidase Glycosidase Phosphatase Inflammation/Immunology
    CH-123 is an orally active lipid-lowering agent. CH-123 inhibits the elevated activities of β-glucuronidase, β-galactosidase, N-acetyl-β-glucosaminidase and acid phosphatase in aortic smooth muscle cells and hepatocytes. CH-123 reduces serum total lipid and cholesterol levels, as well as intracellular cholesterol content in aortic smooth muscle cells. CH-123 significantly inhibits lysosomal enzyme activity. CH-123 can be used in the research of atherosclerosis .
    CH-123
  • HY-182037
    Multi-target kinase-IN-9

    		DNA/RNA Synthesis Pyruvate Kinase Cancer
    Multi-target kinase-IN-9 is a multi-target enzyme inhibitor with antiproliferative and antiangiogenic activities, and exhibits remarkable selectivity against hepatocellular carcinoma cells. By broadly binding to the active sites or ATP-binding regions of multiple key enzymes including DNA polymerase β, Pyruvate Kinase M2 (PKM2), Multi-target kinase-IN-9 comprehensively disrupts DNA repair and replication, glycolysis, chromatin dynamics and transcriptional programs, and blocks the self-renewal of cancer stem cells. Multi-target kinase-IN-9 induces genomic instability, lysosomal dysfunction and autophagic flux impairment, thereby triggering tumor cell death, effectively inhibiting tumor proliferation, invasion, metastasis and angiogenesis, and significantly reducing tumor volume in xenograft models. Multi-target kinase-IN-9 is applicable to hepatocellular carcinoma-related research .
    Multi-target kinase-IN-9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: